286-OR: FGF21 Decreases Hepatic Triglycerides in a Weight Loss-Independent but Sex-Dependent Manner

Fibroblast growth factor-21 (FGF21) decreases hepatic triglycerides when administered to obese animals and humans, and thus has gained attention as a novel drug target for nonalcoholic fatty liver disease (NAFLD). However, its mechanism of action remains unclear. Furthermore, although NAFLD pathology is well known to be sexually dimorphic, studies of FGF21 have skewed toward males without sufficient consideration of sex as a biological variable. Here we report that FGF21 administration to diet-induced obese mice decreased hepatic triglycerides in a weight loss-independent manner in obese male mice, but this effect was blunted in female littermates (p(treatment x sex) Disclosure A. T. B. Chaffin: None. K. R. Larson: None. K. Huang: None. K. K. Ryan: None. Funding National Institutes of Health (R01DK121035, F31DK124080)